CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions

Journal of Thoracic Oncology

Volumn 7, Issue 5, 2012, Pages 883-889

  Blanquart, Christophe ^a   Gueugnon, Fabien ^a   Nguyen, Jean Michel ^a   Roulois, David ^a,b   Cellerin, Laurent ^c   Sagan, Christine ^d   Perigaud, Christian ^c   Scherpereel, Arnaud ^e,f   Gregoire, Marc ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b SEB   (France)

^c Service d'Oncologie Médicale Thoracique et Digestive   (France)

^d CHUde Tours   (France)

^e UNIV LILLE   (France)

^f INSERM   (France)

Author keywords

Diagnosis; Mesothelin; Mesothelioma; Pleural effusions; Tumor markers

Indexed keywords

GALECTIN 3; MESOTHELIN; MESOTHELIN RELATED PEPTIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

AGED; ARTICLE; CELL CULTURE; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PLEURA FLUID; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TUMOR DIFFERENTIATION;

EID: 84862154553     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31824c9272     Document Type: Article

References (24)

1. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79:666-672.
2. Musk AW, de Klerk NH. Epidemiology of malignant mesothelioma in Australia. Lung Cancer 2004;45 Suppl 1:S21-S23.
3. Scherpereel A, Astoul P, Baas P, et al.; European Respiratory Society/European Society of Thoracic Surgeons Task Force. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010;35:479-495.
4. Allen TC. Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies. Arch Pathol Lab Med 2005;129:1415-1420.
5. Miettinen OS, Yankelevitz DF, Henschke CI. Evaluation of screening for a cancer: annotated catechism of the Gold Standard creed. J Eval Clin Pract 2003;9:145-150.
6. Ordóñez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med 2005;129:1407-1414.
7. Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009;133:1317-1331.
8. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 2004;58:24-38.
9. Duffy MJ, van Dalen A, Haglund C, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003;39:718-727.
10. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564-1573.
11. Robinson BW, Creaney J, Lake R, et al. Soluble mesothelin-related protein- a blood test for mesothelioma. Lung Cancer 2005;49 Suppl 1:S109-S111.
12. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155-1160.
13. Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008;85:265-72; discussion 272.
14. Creaney J Robinson BW. Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med 2009;15:366-370.
15. Creaney J, Francis RJ, Dick IM, et al. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res 2011;17:1181-1189.
16. Sapede C, Gauvrit A, Barbieux I, et al. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells. Cancer Sci 2008;99:590-594.
17. Gueugnon F, Leclercq S, Blanquart C, et al. Identification of novel markers for the diagnosis of malignant pleural mesothelioma. Am J Pathol 2011;178:1033-1042.
18. Creaney J, Yeoman D, Naumoff LK, et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007;62:569-576.
19. Davies HE, Sadler RS, Bielsa S, et al. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med 2009;180:437-444.
20. Tomasetti M, Santarelli L. Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application. Cancers 2010;2:523-548.
21. Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci USA 2003;100:5778-5782.
22. Devoogdt N, Rasool N, Hoskins E, Simpkins F, Tchabo N, Kohn EC. Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo. Cancer Sci 2009;100:434-440.
23. Stankovic A, Slavic V, Stamenkovic B, Kamenov B, Bojanovic M, Mitrovic DR. Serum and synovial fluid concentrations of CCL2 (MCP-1) chemokine in patients suffering rheumatoid arthritis and osteoarthritis reflect disease activity. Bratisl Lek Listy 2009;110:641-646.
24. Creaney J Robinson BW. Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am 2005;19:1025-40, v.